Full Press Release Details
Group Reports Record First Quarter 2021 Financial Results
Quarter Revenues Increased 39% to $3.1 Million
FL, April 26, 2021 - Trxade Group, Inc. (NASDAQ:
MEDS), a health services IT company focused on digitalizing the retail pharmacy experience
by optimizing drug procurement, the prescription journey and patient engagement in the U.S.,
today announced its financial results for the first quarter ended March 31, 2021.
Financial Highlights
| $ in millions | Q1 2021 | Q1 2020 | % Increase (Decrease) | |||||||||
| Revenues | $ | 3.1 | $ | 2.2 | 39 | % | ||||||
| Gross Profit | $ | 1.4 | $ | 1.6 | (16 | )% | ||||||
| Gross Profit Percentage | 45 | % | 74 | % | (39 | )% | ||||||
| Net Income (Loss) | $ | (0.7 | ) | $ | 0.2 | (446 | )% | |||||
| Adjusted EBITDA 1 | $ | (0.5 | ) | $ | 0.3 | (244 | )% |
Adjusted EBITDA is a non-GAAP financial measure and is described in relation to its most directly comparable GAAP measure
under "Use of Non-GAAP Financial Information" below.
Quarter 2021 and Subsequent Operational Highlights
| Trxade continued to expand the Trxade drug procurement marketplace nationwide, adding 223 new registered members in Q1 2021, bringing the total registered members to approximately 12,100+. | |
| Signed enterprise retail partnerships to onboard new customers to our telehealth platform, with approximately 500+ stores offering our signature Bonum Health product to thousands of customers spanning all 50 states. | |
| Appointed technology entrepreneur and industry thought leader James Ram to lead the Company's newly launched MedCheks subsidiary in its efforts to bring a Digital Health Passport to market, allowing the holder to display vaccination and COVID-19 testing status. |
are pleased to have started 2021 achieving record first quarter growth, while concurrently making impressive operational progress
spanning all business units," said Suren Ajjarapu, Chairman and Chief Executive Officer, who further stated, "Our
exciting suite of affiliated services - from our comprehensive telehealth solution, to digital health passports enabling
a safe reopening with an attractive pay-per-scan business model - continue to broaden our reach as a company, empowering
independent pharmacies with technology to make them indispensable local health hubs."
have been anything but idle in 2021 and have been pounding the pavement to broaden the reach of our Bonum Health Telehealth partnerships,
signing strategic partnerships with brand-name stores nationwide, such as Kinney Drugs, ProAct, Brookshire Grocery Company, SpartanNash
and most recently, Big Y Foods, as well as others which we've been unable to announce per the terms of our agreements, to
build a truly national platform. Approximately 500+ stores offer Bonum Health services to thousands of users in all 50 states
and we anticipate continued growth in the quarters to come as we ramp up our strategic partnerships and see an increasing number
of employers turning to our turnkey telehealth solution.
Health is focused on bolstering its value proposition and building its brand identity as part of its mission to become a leading
force in the telehealth marketplace. We continue to integrate exciting new solutions into the Bonum Health offering, including
a direct-to-patient prescription drug coupon platform through our partnership with SingleCare, the capability to stream patient
lab results directly into the Bonum Health virtual electronic medical records, and remote patient monitoring. These product enhancements,
paired with our digital marketing strategy, which we are ramping up, provide us with accelerated access into new key markets alongside
our enterprise retail partners."
believe we are incredibly well positioned as we stand today, poised to monetize several emerging revenue streams in addition to
the steady progress made by our high-margin Trxade Exchange core platform. I look forward to aggressive operational execution
in the months ahead as we seek to create sustainable, long-term value for our shareholders," concluded Ajjarapu.
Quarter 2021 Financial Summary
| Revenues for the first quarter of 2021 increased 39% to $3.1 million, as compared to revenue of $2.2 million in the same quarter last year. The increase in revenue was primarily due to higher sales by our Integra Pharma Solutions subsidiary. | ||
| Gross profit in the first quarter of 2021 totaled $1.4 million, or 45% of revenues, compared to gross profit of $1.6 million, or 74% of revenues, in the same quarter last year. The decrease in gross profit was primarily attributable to the cost of Personal Protective Equipment (PPE) related purchased products in the current period, while revenues from the Trxade Platform (which made up the majority of revenues last year) carry no cost of sales. | ||
| Operating expenses in the first quarter of 2021 were $2.0 million, compared to $1.5 million in the same quarter last year. This change is primarily due to IT development, legal expenses and marketing expenses related to the recently launched Bonum Health and MedCheks platforms. | ||
| Net loss in the first quarter of 2021 was $0.7 million, or $0.08 per basic and diluted share outstanding, compared to net income of $0.2 million, or $0.03 per basic share outstanding, in the same quarter last year. | ||
| Adjusted EBITDA, a non-GAAP financial measure, decreased 243% to negative $0.5 million, compared to positive $0.4 million in the same quarter last year. | ||
| Cash and cash equivalents were $5.2 million as of March 31, 2021, compared with $5.9 million as of December 31, 2020. |
will host a conference call on Monday, April 26, 2021 at 5:00 p.m. Eastern time to discuss Trxade Group's first quarter
2021 financial results. The call will conclude with a Q&A from participants. To participate, please use the following information:
2021 Conference Call and Webcast
Monday, April 26, 2021
5:00 p.m. Eastern time
Dial-in: 1-877-425-9470
dial in at least 10 minutes before the start of the call to ensure timely participation.
playback of the call will be available through May 26, 2021. To listen, call 1-844-512-2921 within the United States or 1-412-317-6671
when calling internationally and enter replay pin number 13718446. A webcast will also be available for 30 days on the IR section
of the Trxade Group website or by clicking the webcast link above.
Group (NASDAQ: MEDS) is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug
procurement, the prescription journey and patient engagement in the U.S. The Company operates the TRxADE drug procurement marketplace
serving a total of 12,100+ members nationwide, fostering price transparency and under the Bonum Health brand, offering patient
centric telehealth services. For more information on Trxade Group, please visit the Company's IR website at investors.trxadegroup.com.
of Non-GAAP Financial Information
earnings release discusses EBITDA and Adjusted EBITDA. These measurements are not recognized in accordance with generally accepted
accounting principles (GAAP) and should not be viewed as an alternative to GAAP measures of performance. EBITDA represents net
income before interest, taxes, depreciation and amortization. Adjusted EBITDA is defined as EBITDA before stock-based compensation
expense and gain (loss) in equity investment. EBITDA and Adjusted EBITDA are presented because we believe they provide additional
useful information to investors due to the various noncash items during the period. EBITDA and Adjusted EBITDA have limitations
as analytical tools, and you should not consider them in isolation, or as a substitute for analysis of our operating results as
reported under GAAP. Some of these limitations are: EBITDA and Adjusted EBITDA do not reflect cash expenditures, future requirements
for capital expenditures, or contractual commitments; EBITDA and Adjusted EBITDA do not reflect changes in, or cash requirements
for, working capital needs; and EBITDA and Adjusted EBITDA do not reflect the significant interest expense, or the cash requirements
necessary to service interest or principal payments, on debt or cash income tax payments. Although depreciation and amortization
are noncash charges, the assets being depreciated and amortized will often have to be replaced in the future, and EBITDA and Adjusted
EBITDA do not reflect any cash requirements for such replacements. Additionally, other companies in our industry may calculate
EBITDA and Adjusted EBITDA differently than Trxade Group, Inc. does, limiting its usefulness as a comparative measure. See also
"Reconciliation of Net Income attributable to Trxade Group, Inc., to Earnings before Interest, Taxes, Depreciation and Amortization
(EBITDA) and Adjusted EBITDA", below.
press release may contain forward-looking statements, including information about management's view of Trxade's future
expectations, plans and prospects, within the safe harbor provisions under The Private Securities Litigation Reform Act of 1995
(the "Act"). In particular, when used in the preceding discussion, the words "may," "could,"
"expect," "intend," "plan," "seek," "anticipate," "believe,"
"estimate," "predict," "potential," "continue," "likely," "will,"
"would" and variations of these terms and similar expressions, or the negative of these terms or similar expressions
are intended to identify forward-looking statements within the meaning of the Act, and are subject to the safe harbor created
by the Act. Any statements made in this news release other than those of historical fact, about an action, event or development,
are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause
the results of Trxade, its divisions and concepts to be materially different than those expressed or implied in such statements.
These risks include risks of our operations not being profitable; claims relating to alleged violations of intellectual property
rights of others; technical problems with our websites; risks relating to implementing our acquisition strategies; our ability
to manage our growth; negative effects on our operations associated with the opioid pain medication health crisis; regulatory
and licensing requirement risks; risks related to changes in the U.S. healthcare environment; the status of our information systems,
facilities and distribution networks; risks associated with the operations of our more established competitors; regulatory changes;
healthcare fraud; COVID-19, governmental responses thereto, economic downturns and possible recessions caused thereby; changes
in laws or regulations relating to our operations; privacy laws; system errors; dependence on current management; our growth strategy;
and others that are included from time to time in filings made by Trxade with the Securities and Exchange Commission, including,
but not limited to, in the "Risk Factors" sections in its Form 10-Ks and Form 10-Qs and in its Form 8-Ks, which it
has filed, and files from time to time, with the U.S. Securities and Exchange Commission. These reports are available at www.sec.gov.
Other unknown or unpredictable factors also could have material adverse effects on Trxade's future results and/or could
cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements.
The forward-looking statements included in this press release are made only as of the date hereof. Trxade cannot guarantee future
results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking
statements. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new
information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except
to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that
we will make additional updates with respect to those or other forward-looking statements.
Group - MZ North America
31, 2021 and December 31, 2020
| March 31, 2021 | December 31, 2020 | |||||||
| Assets | ||||||||
| Current Assets | ||||||||
| Cash | $ | 5,209,280 | $ | 5,919,578 | ||||
| Accounts Receivable, net | 1,936,850 | 805,043 | ||||||
| Inventory | 470,122 | 1,257,754 | ||||||
| Prepaid Assets | 457,738 | 151,248 | ||||||
| Other Receivables | 1,081,250 | 1,087,675 | ||||||
| Total Current Assets | 9,155,240 | 9,221,298 | ||||||
| Property Plant and Equipment, Net | 160,647 | 162,397 | ||||||
| Other Assets | ||||||||
| Deposits | 21,636 | 21,636 | ||||||
| Right of use leased assets | 355,693 | 387,371 | ||||||
| Total Assets | $ | 9,693,216 | $ | 9,792,702 | ||||
| Liabilities and Stockholders' Equity | ||||||||
| Current Liabilities | ||||||||
| Accounts Payable | $ | 366,471 | $ | 256,829 | ||||
| Accrued Liabilities | 519,179 | 219,256 | ||||||
| Current Portion Lease Liabilities | 117,030 | 131,153 | ||||||
| Customer Deposits | 10,000 | 10,000 | ||||||
| Notes Payables - Related Party | 225,000 | 225,000 | ||||||
| Total Current Liabilities | 1,237,680 | 842,238 | ||||||
| Long Term Liabilities | ||||||||
| Other Long-Term Liabilities - Leases | 253,912 | 271,306 | ||||||
| Total Liabilities | 1,491,592 | 1,113,544 | ||||||
| Stockholders' Equity | ||||||||
| Series A Preferred Stock, $0.00001 par value; 10,000,000 shares authorized; none issued and outstanding as of March 31, 2021 and December 31, 2020, respectively | - | - | ||||||
| Common Stock, $0.00001 par value; 100,000,000 shares authorized; 8,093,199 shares issued and outstanding as of March 31, 2021 and December 31, 2020 | 81 | 81 | ||||||
| Additional Paid-in Capital | 19,784,616 | 19,610,631 | ||||||
| Accumulated Deficit | (11,583,073 | ) | (10,931,554 | ) | ||||
| Total Stockholders' Equity | 8,201,624 | 8,679,158 | ||||||
| Total Liabilities and Stockholders' Equity | $ | 9,693,216 | $ | 9,792,702 |
Statements of Operations
the Three Months Ended March 31, 2021 and 2020
| 2021 | 2020 | |||||||
| Revenues | $ | 3,053,235 | $ | 2,203,320 | ||||
| Cost of Sales | 1,669,924 | 563,184 | ||||||
| Gross Profit | 1,383,311 | 1,640,136 | ||||||
| Operating Expenses | ||||||||
| General and Administrative | 2,027,566 | 1,451,909 | ||||||
| Operating Income (Loss) | (644,255 | ) | 188,227 | |||||
| Interest net | (7,264 | ) | (7,924 | ) | ||||
| Net Income (Loss) | $ | (651,519 | ) | $ | 180,303 | |||
| Net Income (loss) per Common Share - Basic: | $ | (0.08 | ) | $ | 0.03 | |||
| Net Income (loss) per Common Share - Diluted: | $ | (0.08 | ) | $ | 0.02 | |||
| Weighted average Common Shares Outstanding Basic | 8,093,199 | 6,971,427 | ||||||
| Weighted average Common Shares Outstanding Diluted | 8,093,199 | 7,423,669 |
Statements of Cash Flows